Dr Andy Richards is an entrepreneur and investor with an established track record in founding and scaling up innovative life science, biotechnology and digital health companies in the UK. He is currently Chair of Congenica, Closed Loop Medicine, Arecor Therapeutics, Ieso Digital Health, and Owlstone Medical and is a director of Cancer Research Technology (the commercial board of Cancer Research UK and the Scale-Up Institute.
Andy is an advisor to several investment funds including Cambridge Innovation Capital, the University College London (UCL) Technology Fund, Start Codon and the Cancer Research UK Seed Fund.
Andy is a Cambridge graduate with a PhD in Chemistry and an early career spanning positions with Imperial Chemical Industries (now AstraZeneca) and PA Technology. He was a founder and executive director of Chiroscience plc until its merger with Celltech in 1999. Since that time he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels.
Andy is passionate about science and the translation of science to do good for society. The life sciences and healthcare sectors provide the perfect arena for translating science into technology that can help people around the world. He received a CBE for services to the life sciences in 2015.
Last updated: 7 April 2022